The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
about
Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trialsOld and new treatment targets in axial spondyloarthritisSyndesmophyte growth in ankylosing spondylitisEarly anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis.Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials.Management of arthropathy in inflammatory bowel diseases.Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study.A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE studyEmerging drugs for the treatment of axial and peripheral spondyloarthritis.Pharmacological therapy of spondyloarthritis.Golimumab for the treatment of axial spondyloarthritis.Golimumab for treatment of axial spondyloarthritis.Golimumab: A Review in Inflammatory Arthritis.Secukinumab (AIN457) in the treatment of ankylosing spondylitis.Efficacy and safety of adalimumab in ankylosing spondylitis.Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyStudy protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over tResponse to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych.[What is ascertained in the therapy of axial spondyloarthritis?].Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab.Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria.Golimumab: A Novel Anti-Tumor Necrosis Factor.Inflammation, new bone formation and treatment options in axial spondyloarthritisTherapies in ankylosing spondylitis-from clinical trials to clinical practiceThe current standard of care and the unmet needs for axial spondyloarthritis
P2860
Q26738520-0D1B1E2A-7911-4984-AA19-1AFDD59C4DD0Q26777906-7C6470B7-12E1-4286-8BEE-91D7CB8FF380Q28085617-DD2878D2-F4D2-475A-82A7-4B950C497C39Q33742894-6F213546-131D-4973-BC37-15FB08C3ED25Q34403448-45361900-7B38-4233-9AB7-664D53EC9140Q35091366-42A8713F-5675-4F86-841F-05A5D6788BC1Q35449032-5149ADFC-CB5F-4F28-A035-C3D1E780A4C6Q37369583-856C4C2E-73F2-43FA-AB96-B4BE56746C24Q37539712-6B635416-4BFE-4F36-8E00-B608E9710D1AQ38313266-F881562E-7F1B-43C9-B73F-5C68D13E06BDQ38527552-551158FE-BFB1-4EF0-BEF8-0F676329EB27Q38622217-D0D513E6-2773-441B-A100-0D1A7178A1E3Q38707718-54C6FADC-830D-40FD-A594-217F5F75AAE1Q38771878-236412D3-EBB6-4C35-9BDD-983A1E415802Q38777116-B2597871-F1B2-4763-8B7D-DD7EDCC08625Q38993324-54FAA224-22BB-4628-B1C3-1E216244EBDCQ39477446-D6C241DC-D7DA-45BD-9A97-6D12F0116CB1Q40164708-915621D2-6FE8-49BF-B49B-5F76AC6EE4BEQ44600877-214C12B9-4D3A-4EBD-A9A8-C59A105219BAQ46057173-CE888126-5D4C-4C37-980D-2A272C94447AQ47554166-E5C3B39E-2F21-422F-B826-E529B3238685Q47561517-E33F773B-9103-4449-8E5F-4ACFD6E7BB60Q48224284-B29FA811-0F0C-480D-8686-BA19E72C803BQ53124308-4073FC16-A34A-4380-8331-E2C89C4D35DFQ55008112-608A8DF9-9D58-4A0E-82F3-2B3B01D48A23Q55347433-C393954E-8620-4A99-AF33-81708505423DQ55424021-9F6C1281-BD2F-43D9-9B2E-706D1FD72779Q56964033-9F833FD3-E75A-4C68-8F99-FD0CD1487545Q59125383-E0E9F117-FB19-4E5C-B1BB-E6334E331C8BQ59134860-7B827F79-CFB5-4D71-8373-0383E30ECBD9
P2860
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@en
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@nl
type
label
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@en
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@nl
prefLabel
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@en
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@nl
P2093
P2860
P50
P1476
The effect of two golimumab do ...... 4 years of the GO-RAISE trial.
@en
P2093
Anna Beutler
Atul Deodhar
Jürgen Braun
Stephen Xu
Xenofon Baraliakos
Yiying Zhou
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-203075
P407
P577
2013-05-03T00:00:00Z